Two-year outcomes after sirolimus-eluting stent implantation: Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial

Giora Weisz, Martin B. Leon, David R. Holmes, Dean J. Kereiakes, Mel R. Clark, Barry M. Cohen, Stephen G. Ellis, Patrick Coleman, Carolyn Hill, Chunxue Shi, Donald E. Cutlip, Richard E. Kuntz, Jeffrey W. Moses

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study. BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years. RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8% and 21.3% in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1% versus 24.4% and 12.0% versus 26.7%, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups. CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.

Original languageEnglish (US)
Pages (from-to)1350-1355
Number of pages6
JournalJournal of the American College of Cardiology
Volume47
Issue number7
DOIs
StatePublished - Apr 7 2006
Externally publishedYes

Fingerprint

Sirolimus
Stents
Metals
Thrombosis
Coronary Vessels
Myocardial Infarction
Control Groups

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Weisz, Giora ; Leon, Martin B. ; Holmes, David R. ; Kereiakes, Dean J. ; Clark, Mel R. ; Cohen, Barry M. ; Ellis, Stephen G. ; Coleman, Patrick ; Hill, Carolyn ; Shi, Chunxue ; Cutlip, Donald E. ; Kuntz, Richard E. ; Moses, Jeffrey W. / Two-year outcomes after sirolimus-eluting stent implantation : Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. In: Journal of the American College of Cardiology. 2006 ; Vol. 47, No. 7. pp. 1350-1355.
@article{58f9879f8e7e42ff8973d6eb94880370,
title = "Two-year outcomes after sirolimus-eluting stent implantation: Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial",
abstract = "OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study. BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years. RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8{\%} and 21.3{\%} in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1{\%} versus 24.4{\%} and 12.0{\%} versus 26.7{\%}, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups. CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.",
author = "Giora Weisz and Leon, {Martin B.} and Holmes, {David R.} and Kereiakes, {Dean J.} and Clark, {Mel R.} and Cohen, {Barry M.} and Ellis, {Stephen G.} and Patrick Coleman and Carolyn Hill and Chunxue Shi and Cutlip, {Donald E.} and Kuntz, {Richard E.} and Moses, {Jeffrey W.}",
year = "2006",
month = "4",
day = "7",
doi = "10.1016/j.jacc.2005.11.077",
language = "English (US)",
volume = "47",
pages = "1350--1355",
journal = "Journal of the American College of Cardiology",
issn = "0735-1097",
publisher = "Elsevier USA",
number = "7",

}

Weisz, G, Leon, MB, Holmes, DR, Kereiakes, DJ, Clark, MR, Cohen, BM, Ellis, SG, Coleman, P, Hill, C, Shi, C, Cutlip, DE, Kuntz, RE & Moses, JW 2006, 'Two-year outcomes after sirolimus-eluting stent implantation: Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial', Journal of the American College of Cardiology, vol. 47, no. 7, pp. 1350-1355. https://doi.org/10.1016/j.jacc.2005.11.077

Two-year outcomes after sirolimus-eluting stent implantation : Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial. / Weisz, Giora; Leon, Martin B.; Holmes, David R.; Kereiakes, Dean J.; Clark, Mel R.; Cohen, Barry M.; Ellis, Stephen G.; Coleman, Patrick; Hill, Carolyn; Shi, Chunxue; Cutlip, Donald E.; Kuntz, Richard E.; Moses, Jeffrey W.

In: Journal of the American College of Cardiology, Vol. 47, No. 7, 07.04.2006, p. 1350-1355.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Two-year outcomes after sirolimus-eluting stent implantation

T2 - Results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial

AU - Weisz, Giora

AU - Leon, Martin B.

AU - Holmes, David R.

AU - Kereiakes, Dean J.

AU - Clark, Mel R.

AU - Cohen, Barry M.

AU - Ellis, Stephen G.

AU - Coleman, Patrick

AU - Hill, Carolyn

AU - Shi, Chunxue

AU - Cutlip, Donald E.

AU - Kuntz, Richard E.

AU - Moses, Jeffrey W.

PY - 2006/4/7

Y1 - 2006/4/7

N2 - OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study. BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years. RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8% and 21.3% in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1% versus 24.4% and 12.0% versus 26.7%, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups. CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.

AB - OBJECTIVES: The purpose of this study was to examine the two-year clinical outcomes in patients enrolled in the Sirolimus-Eluting Stent in De Novo Native Coronary Lesions (SIRIUS) study. BACKGROUND: The SIRIUS study was a double-blinded randomized study which demonstrated that sirolimus-eluting stents (SES) significantly improved angiographic results (at 8 months) and clinical outcomes (at 9 and 12 months) compared with bare-metal stents (BMS). METHODS: Patients with de novo native coronary artery lesions randomized to either SES (533 patients) or control BMS (525 patients) were followed for two years. RESULTS: Between one and two years, there were infrequent additional clinical events that were equally distributed between the sirolimus and control groups. After two years, target lesion revascularization was 5.8% and 21.3% in SES and control patients, respectively (p < 0.001), and major adverse cardiovascular events and target vessel failure rates were 10.1% versus 24.4% and 12.0% versus 26.7%, respectively (p < 0.0001 for both). There were no differences in death, myocardial infarction, and stent thrombosis between the two groups. CONCLUSIONS: Clinical outcomes two years after implantation of SES continue to demonstrate significant reduction in the need for repeat target lesion (and vessel) revascularization compared with BMS without evidence for either disproportionate late restenosis or late stent thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=33645416990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645416990&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2005.11.077

DO - 10.1016/j.jacc.2005.11.077

M3 - Article

C2 - 16580520

AN - SCOPUS:33645416990

VL - 47

SP - 1350

EP - 1355

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

SN - 0735-1097

IS - 7

ER -